Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Purchases 261,752 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan purchased 261,752 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the transaction, the chief executive officer now directly owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Raju Mohan also recently made the following trade(s):

• On Friday, November 22nd, Raju Mohan bought 238,248 shares of Ventyx Biosciences stock. The shares were acquired at an average cost of $1.83 per share, for a total transaction of $435,993.84.

Ventyx Biosciences Stock Up 23.3 %

VTYX stock opened at $2.54 on Wednesday. The firm has a 50 day moving average of $2.19 and a two-hundred day moving average of $2.61. Ventyx Biosciences, Inc. has a 12 month low of $1.67 and a 12 month high of $11.48. The company has a market capitalization of $179.60 million, a price-to-earnings ratio of -1.08 and a beta of 0.37.

Institutional Investors Weigh In On Ventyx Biosciences

A number of large investors have recently bought and sold shares of VTYX. Farallon Capital Management LLC acquired a new stake in shares of Ventyx Biosciences in the first quarter worth about $17,435,000. Deerfield Management Company L.P. Series C lifted its holdings in Ventyx Biosciences by 64.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after purchasing an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC boosted its position in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after purchasing an additional 1,193,024 shares during the period. Ikarian Capital LLC grew its holdings in Ventyx Biosciences by 8,483.8% during the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock valued at $2,792,000 after purchasing an additional 501,733 shares during the last quarter. Finally, Vestal Point Capital LP raised its position in shares of Ventyx Biosciences by 31.2% in the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after purchasing an additional 410,000 shares during the period. 97.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VTYX has been the subject of several research reports. Canaccord Genuity Group decreased their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. Wells Fargo & Company decreased their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, November 11th. Finally, Oppenheimer reissued an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.